Abstract:
:Genetic imaging has become an increasingly popular tool that utilizes neuroimaging techniques to investigate the impact of genetic variation on the structure, function and connectivity of the brain. Combining genetic and neuroimaging domains is a promising approach to further the understanding of the neural mechanisms involved in mediating the effect of genetic variants on psychosis risk, with the potential to explore individual vulnerability to psychiatric illness. Imaging genetics approaches have successfully been applied to a wide range of risk genes for schizophrenia. This article reviews the recent literature on genetic imaging in schizophrenia, using two key susceptibility genes for psychosis, DISC1 and NRG1, as examples. The authors explore challenges and future perspectives in the field, including the need for future research to focus on epistatic effects of multiple common variants, account for the complexity of gene-environment interactions, characterize rare high-risk structural variants and identify more effective neuroimaging paradigms that reach a higher threshold of heritability. Ultimately, this review highlights that genetic imaging remains a research technique, and further progress and integration with other techniques will be required before we can predict the onset and development of schizophrenia.
journal_name
Expert Rev Neurotherjournal_title
Expert review of neurotherapeuticsauthors
Redpath HL,Lawrie SM,Sprooten E,Whalley HC,McIntosh AM,Hall Jdoi
10.1586/ern.12.145subject
Has Abstractpub_date
2013-01-01 00:00:00pages
37-47issue
1eissn
1473-7175issn
1744-8360journal_volume
13pub_type
杂志文章,评审abstract::Initial descriptions of bipolar disorder (BD) emphasized that patients returned to a baseline condition after acute episodes. Such definitions were operational in teasing bipolar disorder apart from schizophrenia, where patients were described to be permanently impaired after the initial episodes. However, this view o...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.8.7.1101
更新日期:2008-07-01 00:00:00
abstract::The 10th Global College of Neuroprotection and Neuroregeneration Annual Conference in collaboration with the 6th International Association of Neurorestoratology VI Intercontinental Hotel, Bucharest, Romania, 4-7 April 2013 The 10th Global College of Neuroproetction and Neuroregeneration Annual Conference together with...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1586/14737175.2013.836297
更新日期:2013-10-01 00:00:00
abstract::Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily presents with features of bradykinesia, rigidity and tremor, and has, as part of its core pathology, the degeneration of dopaminergic neurons in the substantia nigra pars compacta. There is a great need for the development of a reliabl...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.8.12.1841
更新日期:2008-12-01 00:00:00
abstract::Since we last addressed the roles of NF-κB and JAK/STAT3 signaling in glioblastoma (GBM) 5 years ago, tremendous strides have been made in the understanding of these two pathways in glioma biology. Contributing to prosurvival mechanisms, cancer stem cell maintenance and treatment resistance, both NF-κB and STAT3 have ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.2014.964211
更新日期:2014-11-01 00:00:00
abstract::Neuroprotective therapy has been proposed for age-related neurodegenerative disorders, including Parkinson's disease. Inhibitors of type B monoamine oxidase (MAOB-Is), rasagiline and (-)deprenyl, are the most promising candidate neuroprotective drugs. Clinical trials of rasagiline in patients with Parkinson's disease ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1586/ern.09.68
更新日期:2009-08-01 00:00:00
abstract:INTRODUCTION:Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS). The modern treatment era for MS witnessed a growing pool of drugs now available for use in clinical practice. These therapies work at different levels, however there is a lack of treatments acting on the neurode...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1080/14737175.2017.1378098
更新日期:2017-11-01 00:00:00
abstract:INTRODUCTION:Pharmaceutical companies and the NIH have invested heavily in a variety of potential disease-modifying therapies for Alzheimer's disease (AD) but unfortunately all double-blind placebo-controlled Phase III studies of these drugs have failed to show statistically significant results supporting their clinica...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1080/14737175.2016.1194203
更新日期:2017-01-01 00:00:00
abstract::Cognitive-behavioral therapy (CBT) originated as a treatment for emotional disorders. However, it is increasingly used to help people with chronic illnesses manage symptoms and improve psychosocial outcomes, such as depression and quality of life. In this article, we focus on uses of CBT in patients with multiple scle...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.10.111
更新日期:2010-09-01 00:00:00
abstract::According to the corticoid receptor hypothesis of depression, hyperactivity of the hypothalamic-pituitary-adrenocortical (HPA) system is one of the major pathophysiological factors for the development of depression and opens a broad range of new antidepressant treatment options that are related to direct interventions...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1586/ern.09.52
更新日期:2009-07-01 00:00:00
abstract:INTRODUCTION:Deep brain stimulation (DBS) has become a standard therapy for the treatment of select cases of medication refractory essential tremor and Parkinson's disease however the effectiveness and long-term outcomes of DBS in other uncommon and complex tremor syndromes has not been well established. Traditionally,...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1080/14737175.2016.1194756
更新日期:2016-08-01 00:00:00
abstract::Attention-deficit/hyperactivity disorder (ADHD) is a common psychiatric condition that affects approximately 5.3% of children worldwide. This disorder is defined by a combination of symptoms of inattention and hyperactivity/impulsivity. Diagnosis is based on impairment in these two domains determining several problems...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.10.17
更新日期:2010-04-01 00:00:00
abstract::Epilepsy is the most common serious neurological disorder in the elderly after stroke and dementia. It may be more important for elderly people because it is intermittent and unpredictable. There is no reliable diagnostic test and so its diagnosis and management requires clinical acumen and experience. The situation i...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.10.170
更新日期:2010-12-01 00:00:00
abstract::Gliomas constitute the most frequent and malignant primary brain tumors. Current standard therapeutic strategies (surgery, radiotherapy and chemotherapeutics, e.g., temozolomide, carmustin or carboplatin) for their treatment are only palliative and survival diagnosis is normally 6-12 months. The development of new the...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.8.1.37
更新日期:2008-01-01 00:00:00
abstract::Introduction: Alzheimer's disease (AD), a commonly encountered neurodegenerative disorder, causes cognitive decline and has a devastating effect on the quality of life. AD occurs mainly through abnormal amyloid β peptide (Aβ) and tau protein (tau) activity around/in neurons. Aβ-based therapeutic techniques have been s...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1080/14737175.2019.1621750
更新日期:2019-07-01 00:00:00
abstract::Translation of the analgesic efficacy of investigational neurotherapeutics from pre-clinical pain models into clinical trial phases is associated with a high risk of failure. Application of human pain biomarkers in early stages of clinical trials can potentially enhance the rate of successful translation, which would ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.2014.884925
更新日期:2014-03-01 00:00:00
abstract::Zonisamide (Zonegran, Eisai, Inc.) is a broad spectrum antiepileptic drug indicated for use as adjunctive therapy in the treatment of partial seizures. Zonisamide has multiple mechanisms of action, which may explain widespread reports of its utility in focal epilepsy and generalized epilepsy, and for nonseizure disord...
journal_title:Expert review of neurotherapeutics
pub_type: 历史文章,杂志文章,评审
doi:10.1586/14737175.4.6.935
更新日期:2004-11-01 00:00:00
abstract::Sumatriptan 85 mg with naproxen sodium 500 mg, a combination tablet for the acute treatment of migraine, is approved in the USA. It is likely that triptan/NSAID combination benefits are a class effect, although the majority of data are on sumatriptan and naproxen sodium. The combination tablet demonstrated superior ef...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.8.9.1289
更新日期:2008-09-01 00:00:00
abstract:INTRODUCTION:Therapy with current antiepileptic drugs aims at reducing the likelihood of seizure occurrence rather than influencing the underlying disease process. Therefore, antiepileptic drugs have an anticonvulsant rather than antiepileptic property. Areas covered: The increasing identification of genetic causes for...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1080/14737175.2017.1253476
更新日期:2017-04-01 00:00:00
abstract::Trigeminal neuralgia (TN) and persistent idiopathic facial pain (PIFP) are two of the most puzzling orofacial pain conditions and affected patients are often very difficult to treat. TN is characterized by paroxysms of brief but severe pain followed by asymptomatic periods without pain. In some patients a constant dul...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.11.156
更新日期:2011-11-01 00:00:00
abstract::Alzheimer's disease (AD) is the most common CNS disorder occurring worldwide. There is neither proven effective prevention for AD nor a cure for patients with this disorder. Hence, there is an urgent need to develop safer and more efficacious drugs to help combat the tremendous increase in disease progression. The pre...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.2015.988709
更新日期:2015-01-01 00:00:00
abstract::With improved control of the immunological phenomena of systemic lupus erythematosus, the epidemiology of this disease is changing. While both cardiac and neurological manifestations of systemic lupus erythematosus have been consistently described, there is increasing awareness of the need for general cardiovascular p...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1586/14737175.2.3.385
更新日期:2002-05-01 00:00:00
abstract::Persistent gait deficits after stroke can cause falls, elevated energy cost and poor endurance. Coordination impairment is an underlying cause of gait deficits. Few efficacious interventions have been described that have targeted and measured restoration of coordinated gait components. Neuromuscular electrical stimula...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.6.10.1511
更新日期:2006-10-01 00:00:00
abstract::With the development of new immunomodulating therapies, with which early use is strongly encouraged, it is crucial to be in possession of reliable clinical predictors of multiple sclerosis evolution. Prognostic factors are important to patients wanting to be informed about their prospects; to the clinician needing to ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.6.3.357
更新日期:2006-03-01 00:00:00
abstract:INTRODUCTION:Calcitonin Gene-Related Peptide (CGRP) has gradually emerged as a suitable therapeutic target to treat migraine. Considering the social and economic burden of migraine, it is fundamental to optimize the disease management with efficacious and safe treatments. In this scenario, drugs targeting GCRP, monoclo...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1080/14737175.2020.1772758
更新日期:2020-06-01 00:00:00
abstract::The third part of this in-depth review series on the treatment of multiple sclerosis (MS) with monoclonal antibodies covers the years 2010-2012. The natalizumab section gives a progressive multifocal leukoencephalopathy update, focusing on clinically relevant aspects. Furthermore, it outlines problems around natalizum...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/ern.13.17
更新日期:2013-03-01 00:00:00
abstract::Cluster headache is one of the primary headache disorders. It is considered the most severe headache syndrome known to humans. In most instances, this disorder is readily treatable when the correct medications are utilized at the correct dosages. Cluster headache treatment involves abortive, transitional and preventiv...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1586/14737175.2.3.295
更新日期:2002-05-01 00:00:00
abstract::Attention deficit hyperactivity disorder (ADHD) is a common behavioral disorder of a complex nature. Genetic and environmental factors are thought to be involved in precipitating the disorder. Pharmacological, animal model and recent molecular studies support the role of genes (of minor or medium effect) from dopamine...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章
doi:10.1586/14737175.3.4.453
更新日期:2003-07-01 00:00:00
abstract::Intraoral splints are effective in migraine prevention. In this review, changes in the quality of life of migraineurs treated with a palatal nonoccluding splint were measured. Using the Migraine Specific Quality of Life Instrument (Version 2.1), it was found that the palatal nonoccluding splint significantly improved ...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.5.3.371
更新日期:2005-05-01 00:00:00
abstract::With increasing life expectancy, the early diagnosis and treatment of Alzheimer's disease has become critical in sustaining a healthy society. Noninvasive markers of disease progression starting from the earliest stages of pathologic involvement are required for determining the effectiveness of putative disease-modify...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.5.5.663
更新日期:2005-09-01 00:00:00
abstract::Estrogens fluctuations, particularly their premenstrual fall, are currently regarded as the main triggers of menstrual migraine (MM). MM presents in two clinical forms: pure MM, where attacks are confined to the perimenstrual period (PMP), and menstrually related migraine, where attacks always occur during, but are no...
journal_title:Expert review of neurotherapeutics
pub_type: 杂志文章,评审
doi:10.1586/14737175.7.9.1105
更新日期:2007-09-01 00:00:00